Every material Form 8-K Medline Inc. has filed with the SEC since October 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Medline reported third quarter 2026 net sales of $7.9 billion, up 10.4%, while net income fell 1.2% to $318 million, with the company citing higher inventory costs, operating expenses and customer mix, partly offset by $81 million of net IEEPA tariff refund benefits. The company raised its full-year 2026 Organic Sales growth outlook to 10.0% to 10.5%, reaffirmed Adjusted EBITDA guidance of $3.3 billion to $3.4 billion, and its board authorized a $1 billion share repurchase program.
Q3 2026 net income was $318 million, down from $322 million; diluted EPS was $0.22
Q3 2026 Adjusted EBITDA rose 11.8% to $960 million from $859 million
Full-year 2026 Organic Sales growth guidance raised to 10.0% to 10.5% from 9.0% to 10.0%; Adjusted EBITDA guidance reaffirmed at $3.3 billion to $3.4 billion
Board approved a $1 billion share repurchase program in October 2026, and $750 million of the 2033 Refinancing Term Loan Facility was prepaid
Medline initiated a voluntary field action on October 14, 2026, to remove, discontinue, and exit the market for all Medline Brand beds, along with related pendants, accessories, parts, and order packages. The company estimates associated costs of up to $220 million, to be incurred in 2026 and 2027 and excluded from Adjusted EBITDA, which is a clear charge for shareholders, though it does not currently expect a material impact on fiscal 2026 financial results or its full-year 2026 guidance.
Voluntary field action initiated October 14, 2026, covering all Medline Brand beds, including homecare, bariatric, and long-term care beds.
Affected products had net sales of approximately $60 million for the twelve months ended June 27, 2026.
Estimated associated costs of up to $220 million, expected in 2026 and 2027, to be excluded from Adjusted EBITDA; actual customer credits may differ materially.
Company does not currently expect a material impact on fiscal 2026 results, including full-year 2026 guidance provided August 5, 2026.
Medline Inc. disclosed that director Joseph P. Baratta notified the Board on October 13, 2026 that he will resign, effective December 31, 2026. The company said the decision coincides with his previously announced departure from Blackstone Inc. and is not due to any disagreement over company operations, policies, or practices.
Joseph P. Baratta notified the Board on October 13, 2026 of his decision to resign.
Resignation is effective December 31, 2026.
Company states there was no disagreement with management related to operations, policies, or practices.
Filing was signed by Chief Legal Officer Alex M. Liberman on October 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Medline Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →